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Atrial fibrillation (AF) is a common and devastating cardio-embolic cause of stroke.1 Treatment with anticoagulants 
reduces the risk of recurrent stroke by 39% to 63% compared 
with treatment with antiplatelet agents.2,3 However, because of 
its paroxysmal nature, AF often goes undetected,4,5 leaving a 
considerable proportion of patients under suboptimal protec-
tion for recurrent stroke.
In patients with acute ischemic stroke (AIS) treated with 
endovascular treatment (EVT) for a large vessel occlusion, 
various thrombus characteristics can be assessed on admission 
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computed tomography (CT) and CT angiography (CTA). If 
a relationship between a cardioembolic stroke cause and 
thrombus CT characteristics exists, assessing these character-
istics in clinical practice could serve as a useful additional tool 
to identify patients with covert AF or other cardioembolic risk 
factors for stroke and serve as a reason to intensify diagnostic 
workup for a cardioembolic source in these patients.
Recent histological studies have described the relationship 
of stroke cause with the histological composition of retrieved 
thrombi during EVT for AIS.6,7 One of the most important 
findings of these studies was that fibrin-rich (red blood cell 
[RBC]-poor) thrombi were associated with a cardioembolic 
cause of stroke. In addition, thrombus histological composi-
tion was shown to be related to thrombus attenuation increase 
(TAI), a measure for thrombus permeability, which in turn 
is related to thrombus length and location.8–10 Furthermore, 
earlier work has described the correlation between thrombus 
RBC-content and thrombus attenuation on CT imaging.11
Evidence of the relationship of stroke cause with 
thrombus imaging characteristics is limited, and studies, so 
far, are small and have mainly focused on the hyperdense 
artery sign (HAS), which is an ill-defined measure with 
moderate interobserver variability,12 or on thrombus perme-
ability.8,9 Our purpose was to study the relationship between 
stroke cause and various thrombus CT characteristics in a 
large, multi-center cohort of patients with ischemic stroke 
due to an acute large vessel occlusion.
Methods
Study Population
The MR CLEAN Registry (Multicenter Randomized Clinical Trial of 
Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) 
is a prospective observational study of all patients that underwent 
EVT for AIS in the Netherlands.13 Enrollment started on 16 March, 
2014, directly after the final randomization in the MR CLEAN trial. 
All patients undergoing EVT (defined as at least entry into the angi-
ography suite and receiving arterial puncture) for AIS in the anterior 
or posterior circulation, treated in one of the 16 centers performing 
EVT in the Netherlands, were registered. The central medical ethics 
committee of the Erasmus Medical Center Rotterdam, the Netherlands 
evaluated the study protocol and granted permission to carry out the 
study as a registry (MEC-2014–235). Patients who met the following 
criteria were included in the present substudy: age 18 years and older 
and a proximal intracranial vessel occlusion in the anterior circulation, 
as shown on CTA. Data of consecutive patients treated until 15 June, 
2016 was collected and analyzed for this study. Data cannot be made 
available, as no patient approval has been obtained for sharing coded 
data. However, syntax files and output of statistical analyses in STATA 
are available from the corresponding author on reasonable request.
Assessment of Stroke Cause
All patients underwent CTA or magnetic resonance angiography of 
the cervical arteries and 12-lead ECG followed by ECG-monitoring 
for at least 24 hours. Additional etiologic work-up was performed in 
accordance with local protocols. Stroke cause was determined from 
information in discharge letters and imaging by 2 trained observ-
ers, blinded for thrombus imaging characteristics. Each patient was 
allocated to one of 4 predefined etiologic categories, as defined by 
the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) cri-
teria14: large artery atherosclerosis (TOAST 1), cardioembolism 
(TOAST 2), stroke of other determined cause (TOAST 4), and stroke 
of undetermined cause (TOAST 5). In our cohort of patients who 
underwent EVT for AIS, there were no patients with small vessel 
disease (TOAST 3). A patient was considered to have large artery 
atherosclerosis stroke if there was >50% atherosclerotic stenosis 
or atherosclerotic occlusion at the bifurcation of the carotid artery 
on the symptomatic side. Patients were considered to have undeter-
mined stroke cause if >1 possible cause was identified, if no cause 
was identified despite complete work-up as described above (cryp-
togenic stroke), or if diagnostic workup was incomplete. For most 
analyses, TOAST 1 and 4 were combined into one category, defined 
as noncardioembolic strokes.
Image Analysis
An imaging core laboratory consisting of 21 observers (20 interven-
tional neuroradiologists and 1 interventional neurologist, blinded for 
all clinical information except symptom side) determined presence of 
HAS, clot burden score (CBS), and thrombus location. CBS ranges 
from 0 to 10 and describes thrombus extent; a score of 10 is normal, 
a score of 0 implies complete multisegment vessel occlusion.15 
Thrombus location (internal carotid artery [ICA], ICA-terminus 
[ICA-T], M1, M2, M3, A1, or A2) was based on the most proximal 
occluded segment on CTA.
Additionally, 2 neuroradiologists (Dr Dutra and Alves) blinded 
for stroke cause, determined absolute thrombus attenuation, relative 
thrombus attenuation, distance from the ICA-T to the thrombus (DT), 
thrombus length, and TAI in a subset of patients with available thin-sec-
tion (≤2.5 mm) noncontrast computed tomography (NCCT) and CTA 
imaging, acquired within 30 minutes from each other.16 All baseline 
NCCT and CTA images were automatically aligned using rigid regis-
tration with Elastix software.17 In case of suboptimal alignment, adjust-
ments were performed using manual rigid registration with Mevislab 
(by Dr Dutra). Scans with uncorrectable registration errors, artifacts, 
excessive noise, or poor contrast opacification on CTA were excluded. 
To prevent bone artefacts that might interfere with thrombus attenu-
ation measurements, we also excluded patients with an intracranial 
occlusion restricted to the petrous, cavernous, and clinoid segments of 
the ICA. Calcified thrombi were excluded because of their higher at-
tenuation values (related to calcium composition) compared with the 
attenuation values of noncalcified thrombi, and because calcification 
produces streak and partial volume artifacts, which can cause over-
estimation of thrombus size. In case of a pseudo-occlusion, the HAS 
on the co-registered NCCT was used as the proximal thrombus border.
Assessment of absolute attenuation, relative attenuation and 
TAI was adapted from Santos et al.18,19 In short, absolute attenuation 
was estimated as the mean value of 3 regions of interest on NCCT 
with a radius of 1 mm in the proximal, middle, and distal part of the 
thrombus. Subsequently, 3 regions of interest were placed in the con-
tralateral artery. Relative attenuation was calculated by dividing the 
mean attenuation values of the 3 regions of interests in the thrombus 
by the mean attenuation of the 3 regions of interests in the contra-
lateral artery. TAI was assessed by subtracting the thrombus’ mean 
attenuation on NCCT from its mean attenuation on CTA. Thereby, 
TAI represents the permeability of thrombus for contrast material, 
measured on single-phase imaging.
Thrombus length was assessed on NCCT with the aid of co-regis-
tered CTA, using multiplanar reformations, and was estimated by the 
filling defect in the occluded vessel on CTA. Whenever the proximal or 
distal part of thrombus could not be depicted on CTA, thrombus length 
was based on the HAS assessed on the co-registered NCCT. DT was 
measured manually on CTA and represents the distance from the ICA-T 
to the beginning of the thrombus. For thrombi located in the supra-clinoid 
segment of the ICA but not extending into the ICA-T, DT was set to 0.
Statistical Analysis
Clinical characteristics and thrombus imaging characteristics were 
described using standard statistics. We compared thrombus charac-
teristics (presence of HAS, CBS, thrombus location, absolute atten-
uation, relative attenuation, DT, length, and TAI) of cardioembolic 
strokes (reference group) with noncardioembolic strokes and strokes 
with undetermined cause. The association of stroke cause with HAS 
was estimated with univariable and multivariable binary logistic 
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regression and presented as (adjusted) odds ratios (OR) with 95% CI. 
We estimated the association of stroke cause with CBS and thrombus 
location with ordinal logistic regression and results were expressed as 
(adjusted) common OR’s (cOR) for shift towards a one-point higher 
CBS or a more distal thrombus location (ICA; ICA-T; proximal M1; 
distal M1; M2/M3), respectively. For analyses that involved thrombus 
location as an ordinal variable, A1/A2-occlusions were left out. The 
association of stroke cause with absolute attenuation, relative attenu-
ation, DT, length, and TAI was estimated with univariable and multi-
variable linear regression and was presented as (adjusted) coefficients 
(β) with 95% CI. We adjusted for potential confounding by including 
the following characteristics as covariates in the multivariable mod-
els: age, sex, administration of intravenous alteplase duration from 
stroke onset to imaging, and thrombus location. Selection of these 
variables was based on evidence from previous studies and clinical 
knowledge. All characteristics with a P<0.10 (in the univariable anal-
ysis) were included in the multivariable analysis, except for age and 
sex, which were included in all multivariable models, based on clin-
ical knowledge. The analyses that involved CBS and DT were not 
adjusted for thrombus location, because of collinearity.
To increase comparability with other studies, we performed a sen-
sitivity analysis in which we compared patients with cardioembolic 
stroke (reference) to large-artery atherosclerosis stroke (instead of 
all noncardioembolic strokes) and cryptogenic stroke (undetermined 
cause and complete workup). For the regression analyses, miss-
ing data were imputed using single imputation. The variables that 
were imputed are listed in the Data Supplement (Table I in the Data 
Supplement). STATA/SE 15.1 (StataCorp, College Station Texas) 
was used for all statistical analyses.
Results
Patient Population
Of the 1627 patients enrolled in the MR CLEAN Registry 
from March 2014 until June 2016, 101 were excluded be-
cause of age under 18 years, treatment in a non-MR CLEAN 
trial hospital, or a posterior circulation occlusion, and 97 
patients were excluded because no discharge letter was 
available. Therefore, 1429 patients were available for anal-
ysis of the association between stroke cause, presence of 
HAS, CBS, and thrombus location (Figure I in the Data 
Supplement). The median age was 71 (interquartile range 
[IQR], 60–80) years, and 762 (53%) were men (Table 1). 
Median time from stroke onset to admission imaging was 
72 minutes (IQR, 53–137) for noncardioembolic strokes, 
76 minutes (IQR, 52–146) for cardioembolic strokes, and 
76 minutes (IQR, 54–134) for strokes with undetermined 
cause. There was no significant difference in time from onset 
to admission imaging between the different stroke subtypes. 
For the additional measurements, 367 patients with thin-
section imaging were available for analysis. Patients with 
and without available thin-section imaging for thrombus 
measurements showed similar baseline and imaging charac-
teristics, with the exception of a slightly higher prevalence 
of a distal M1 occlusion in the thin-section imaging group 
(Table II in the Data Supplement).
One-hundred ninety (13%) patients had large artery ath-
erosclerosis, 476 (33%) cardioembolism, 67 (5%) other de-
termined cause (of which 44 carotid artery dissection), and 
696 (49%) stroke of undetermined cause. AF was the most 
common (n=365, 84%) cardioembolic cause of stroke. Of 
the patients with an undetermined stroke cause, 78 had >1 
identified cause of stroke, 458 cryptogenic stroke, and 160 
incomplete workup.
Imaging Characteristics
HAS was present in 55% of patients. Three hundred-sixty-
nine (31%) patients had a CBS of 0 to 4, 499 (42%) of 5 
to 7, and 336 (28%) of 8 to 10. Thrombi were most often 
located in the distal part of the M1-segment of the middle ce-
rebral artery (MCA; n=442, 32%), followed by the proximal 
M1-segment of the MCA (n=352, 26%), the ICA-T (n=308, 
23%), the M2-segment of the MCA (n=158, 12%), and the 
intracranial ICA (n=83, 6%). In a small group of patients 
(n=21, 2%), the thrombus was located in the M3-segment 
of the MCA (n=6), in the anterior (A1/A2) cerebral artery 
(n=5), or no definitive occlusion was present according to 
the core laboratory (n=10; Table 1).
The thrombus imaging measurements of this cohort were 
previously published.16 Median absolute thrombus attenuation 
was 52.2 (IQR, 45.9–58.6) HU, the median relative thrombus 
attenuation was 1.3 (IQR, 1.2–1.5) HU, the median DT was 
7.8 (IQR, 0–13.9) mm, the median thrombus length was 13.5 
(IQR, 9.3–18.6) mm, and the median TAI was 5.0 (IQR, −0.5 
to 11.7) HU (Table 2). Figures 1 and 2 show various thrombus 
characteristics, stratified by stroke cause.
Cardioembolic Versus Noncardioembolic Strokes
Thrombus CT characteristics of noncardioembolic strokes 
were different from those of cardioembolic strokes in the 
unadjusted and adjusted analyses (Tables 3 and 4). In uni-
variable analysis, noncardioembolic strokes were associ-
ated with presence of HAS (OR, 2.2 [95% CI, 1.6–3.0]), 
lower CBS (cOR, 0.4 [95% CI, 0.3–0.6]), shift towards 
a more proximal thrombus location (cOR, 0.2 [95% CI, 
0.2–0.3]), higher absolute thrombus attenuation (β, 3.6 
[95% CI, 0.9–6.4]), decrease in DT (β, −5.7 [95% CI, −8.3 
to −3.0]), and longer thrombi (β, 8.6 [95% CI, 6.5–10.7]), 
compared with a cardioembolic cause (Tables 3 and 4). 
After adjusting for the prespecified variables, all associ-
ations remained present, except for the association of a 
noncardioembolic cause with HAS and higher absolute 
thrombus attenuation.
Strokes With Undetermined Cause
Thrombus imaging characteristics for strokes with undeter-
mined cause were similar to those of cardioembolic strokes 
(Tables 3 and 4). There was no difference in presence of 
HAS (OR, 1.1 [95% CI, 0.8–1.3]), CBS (cOR, 0.9 [95% CI, 
0.8–1.1]), absolute thrombus attenuation (β, −1.1 [95% CI, 
−3.1 to 1.0]), relative thrombus attenuation (β, −0.0 [95% 
CI, −0.1 to 0.0]), DT (β, −0.3 [95% CI, −2.3 to 1.7]), length 
(β, 0.3 [95% CI, −1.3 to 1.9]), or TAI (β, 2.4 [95% CI, −1.7 
to 6.6]). In the multivariable analyses, none of these results 
changed. Strokes with undetermined cause were associated 
with a slightly more proximal thrombus location (cOR, 0.8 
[95% CI, 0.6–0.9]). This association was not present in the 
multivariable analysis.
Sensitivity Analyses
Our sensitivity analysis yielded in general the same results as 
our main analysis (Tables III and IV in the Data Supplement). 
In our main analysis, strokes with undetermined cause were 
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associated with a slightly more proximal thrombus location 
than cardioembolic strokes (cOR, 0.8 [95% CI, 0.6–0.9]). 
Reducing this group to cryptogenic strokes only, made this 
difference disappear (cOR, 0.9 [95% CI, 0.7–1.1]).
Discussion
This study shows that in patients who underwent EVT for 
AIS, (1) thrombus CT characteristics of cardioembolic stroke 
are distinct from those of noncardioembolic stroke and that 
Table 1. Baseline and Imaging Characteristics of Patients in the MR CLEAN Registry, Stratified by Stroke Cause
Characteristics Noncardioembolic (n=257) Cardioembolic (n=476) Undetermined (n=696) Total (n=1429)
Median age (IQR), y 67 (58–75) 76 (67–83) 68 (55–78) 71 (60–80)
Men 164 (64) 223 (47) 375 (54) 762 (53)
Median (IQR) NIHSS score 16 (12–20) 16 (12–20) 16 (11–20) 16 (11–20)
Intravenous alteplase treatment 215 (84) 291 (61) 586 (84) 1092 (76)
Median (IQR) time from stroke onset to 
admission imaging*
72 (53–137) 76 (52–146) 76 (54–134) 76 (53–76)
Median (IQR) time from stroke onset to groin 
puncture
210 (170–270) 210 (160–270) 210 (160–270) 210 (160–270)
Medical history
Ischemic stroke 34 (14) 89 (18) 113 (16) 236 (17)
Atrial fibrillation† 0 (0) 281 (61) 46 (7) 327 (24)
Myocardial infarction 29 (12) 77 (17) 110 (16) 216 (15)
Peripheral artery disease 31 (12) 47 (10) 56 (8) 134 (10)
Drug use
Antiplatelet 81 (32) 146 (31) 236 (34) 463 (33)
Coumarine 4 (2) 150 (32) 36 (5) 190 (13)
Direct-acting oral anticoagulant 1 (0) 27 (6) 9 (1) 37 (3)
Imaging characteristics
Hyperdense artery sign 171 (70) 229 (51) 337 (51) 737 (55)
Median (IQR) Clot Burden Score 5 (3–6) 6 (5–8) 6 (4–8) 6 (4–8)
Occlusion location
Intracranial ICA 39 (15) 6 (1) 38 (6) 83 (6)
ICA-terminus 91 (36) 81 (18) 136 (21) 308 (23)
Proximal M1 66 (26) 119 (26) 167 (25) 352 (26)
Distal M1 47 (19) 171 (38) 224 (34) 442 (32)
M2 10 (4) 68 (15) 80 (12) 158 (12)
Other‡ 1 (0) 6 (1) 14 (2) 21 (2)
Values are numbers (percentages) of patients unless stated otherwise. ICA indicates internal carotid artery; IQR, interquartile range; MR CLEAN, Multicenter Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NIHSS, National Institutes of Health Stroke Scale; and M1/M2 middle cerebral artery.
*Admission imaging that was used to assess thrombus imaging characteristics for the current study.
†Forty-six patients with undetermined cause had more than one cause of stroke, of which one was atrial fibrillation.
‡In 6 patients the occlusion location was considered to be in the M2 at the moment endovascular treatment was decided, but the imaging core laboratory observed 
an M3 occlusion. Five patients had a proximal occlusion in the anterior cerebral artery. Ten patients underwent endovascular treatment without a definitive occlusion on 
computed tomography angiography according to the core laboratory.
Table 2. Thrombus Characteristics on Thin-Section (≤2.5 mm) Admission Imaging (n=367), Stratified by Stroke Cause; Values Are Medians (IQR)
Characteristics Noncardioembolic (n=61) Cardioembolic (n=125) Undetermined (n=181) Total (n=367)
Absolute attenuation, HU 57.4 (51.4 to 61.4) 51.9 (46.6 to 57.3) 50.7 (44.1 to 57.7) 52.2 (45.9 to 58.6)
Relative attenuation 1.5 (1.3 to 1.6) 1.4 (1.3 to 1.5) 1.3 (1.2 to 1.5) 1.3 (1.2 to 1.5)
DT, mm 0 (0 to 7.7) 8.6 (0 to 14.4) 9.3 (2.1 to 14.3) 7.8 (0 to 13.9)
Length, mm 21.0 (13.4 to 28.6) 12.3 (9.0 to 16.5) 12.8 (8.7 to 17.2) 13.5 (9.3 to 18.6)
TAI, HU 5.7 (0.2 to 12.5) 3.9 (−1.5 to 11.1) 5.2 (0.8 to 12.0) 5.0 (−0.5 to 11.7)
DT indicates distance from the internal carotid artery-terminus to the thrombus; HU, Hounsfield units; IQR, interquartile range; and TAI, thrombus attenuation increase
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(2) there is a similarity between thrombus CT characteristics 
of cardioembolic stroke and stroke with undetermined cause. 
To our knowledge, this is the largest study of thrombus CT 
characteristics with stroke cause so far.
Cardioembolic strokes were associated with absence of 
HAS and lower absolute thrombus attenuation (Tables 3 and 
4). Since the positive correlation of thrombus attenuation with 
RBC-content is clearly described,11,20,21 our findings suggest 
cardioembolic thrombi tend to be lower in RBC-content. This 
is in line with results from recent histological studies,6,7 which 
showed that cardioembolic thrombi are high in fibrin-content 
and low in RBC-content compared with noncardioembolic 
thrombi. Our results seem to be in contrast with those of a 
recent review on various histological and imaging character-
istics of thrombi,11 in which no relationship between stroke 
cause and HAS or thrombus attenuation was found. However, 
a considerable proportion of studies that were included in this 
review, did observe a nonsignificant trend towards absence of 
HAS for patients with cardioembolic stroke.
Compared with cardioembolic thrombi, noncardioem-
bolic thrombi were longer and were found at a more prox-
imal location (Tables 3 and 4). In a previous study, we have 
reported the correlation between thrombus length and loca-
tion.16 One can reason that thrombi, when they are smaller, 
can travel further into the intracranial circulation. This is in 
line with the findings of Marder et al,22 who showed that the 
ultimate destination of the thrombus is related to its width. 
Even though we assessed thrombus length and not width in 
the current study, we hypothesize that thrombus length is 
related to its width and that longer thrombi have more diffi-
culty moving past vascular curves. A possible limitation of 
the current study could be that assessing thrombus length 
on imaging might be more difficult for distally located 
thrombi. However, the relationship between stroke cause 
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Figure 1. Thrombus characteristics for different stroke etiologies are shown. Patients with noncardioembolic stroke more often had hyperdense artery sign 
(HAS; A) and a proximal thrombus location (B) than patients with cardioembolic stroke and undetermined cause stroke. Noncardioembolic indicates large-
artery atherosclerosis and other determined cause. ICA indicates internal carotid artery; ICA-T, ICA terminus; pM1, proximal M1 and dM1, distal M1.
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Figure 2. Thrombus characteristics for different stroke etiologies are shown. Noncardioembolic strokes had higher absolute thrombus attenuation in Hounsfield 
units (A) and longer thrombi (B), compared with the other etiologies. Noncardioembolic indicates large-artery atherosclerosis and other determined cause.
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and thrombus length remained significant after adjusting 
for thrombus location, suggesting an independent relation-
ship of length with cause.
We did not find a relationship between stroke cause 
and TAI and relative thrombus attenuation, which is in 
contrast with recent findings of Berndt et al,9 who found 
an association between cardioembolic thrombi and higher 
thrombus permeability, and those of Puig et al,23 who 
found an association between cardioembolic thrombi and 
higher relative attenuation. Differences in results could 
have been caused by the fact that both studies include 
patients with ischemic stroke with an LVO restricted to 
the MCA; therefore, their results may not be fully com-
parable to our cohort of patients with LVO of the anterior 
circulation. Furthermore, both studies have considerable 
smaller sample size. Finally, the method the authors used 
to measure relative thrombus attenuation, differed from 
the one used in our study.
Are Cryptogenic Strokes Cardioembolic Strokes?
We observed a strong similarity between thrombus charac-
teristics of cardioembolic strokes and those of strokes with 
undetermined cause. These findings complement recent 
results of histological studies6,7,9 that also show a strong 
similarity between thrombi in patients with cardioembolic 
strokes and strokes of undetermined cause. Based on these 
data, it seems considerably likely that many cryptogenic 
strokes have a cardioembolic origin. This theory is under-
lined by a recent randomized controlled trial of enhanced 
and prolonged monitoring for AF after ischemic stroke, 
which showed substantially higher detection rate of AF in 
the monitoring group4 and by a recent meta-analysis24 that 
showed similar results.
Implications for Clinical Practice
Currently, between one-third to half of ischemic strokes has 
no known cause following thorough diagnostic evaluation,25 
which complicates effective secondary stroke prevention. The 
current literature supports the hypothesis that cryptogenic 
strokes are, for a large part, cardioembolic; however, it is not 
yet clear which patients with cryptogenic stroke should be 
submitted to prolonged or enhanced cardiac follow-up. In the 
current study, we show that thrombus characteristics derived 
from admission CT imaging are related to stroke cause. Future 
research should focus on the value of these characteristics as a 
diagnostic tool for stroke cause, or for the selection of patients 
with cryptogenic stroke that would benefit most from addi-
tional diagnostic workup for a cardioembolic source.
Limitations
Our study has several limitations. First, 49% of patients had an 
undetermined stroke cause; a large proportion, compared with 
other studies.26 In part, this can be explained by the absence 
of patients with small vessel disease in a cohort of patients 
who underwent EVT for large vessel occlusion. Furthermore, 
detailed information on rhythm monitoring and echocardiog-
raphy were unavailable for some patients, and a proportion of 
patients with undetermined cause may have had an identifi-
able cardioembolic source; a result of a registry of daily clin-
ical practice. It is important to realize that the overall interrater 
agreement of the TOAST classification system is regarded as 
moderate,27 although reliability varies between stroke sub-
types. However, this system was most suitable for our registry 
of clinical practice, and its wide use allowed for comparison 
of our results with those of other studies.
Second, by studying 8 thrombus characteristics as out-
come measures and, therefore, conducting multiple statistical 
Table 4. Univariable and Multivariable Linear Regression for the Relationship Between Stroke Cause and Thrombus Characteristics on Thin-Section Imaging (n=367)
Absolute Attenuation Relative Attenuation DT Length TAI
β (95% CI) aβ* (95% CI) β (95% CI) aβ† (95% CI) β (95% CI) aβ‡ (95% CI) β (95% CI) aβ* (95% CI) β (95% CI) aβ† (95% CI)
Cardioembolic 
(reference)
0 0 0 0 0 0 0 0 0 0
Noncardioembolic 3.6  
(0.9 to 6.4)
1.0  
(−1.8 to 3.8)
0.0  
(−0.1 to 0.1)
0.0  
(−0.1 to 0.1)
−5.7  
(−8.3 to −3.0)
−6.1  
(−8.8 to -3.4)
8.6  
(6.5 to 10.7)
6.2  
(4.1 to 8.3)
2.1  
(−3.5 to 7.7)
2.8  
(−2.8 to 8.5)
Undetermined 
cause
−1.1  
(−3.1 to 1.0)
−1.5  
(−3.5 to 0.5)
−0.0  
(−0.1 to 0.0)
−0.0  
(−0.1 to 0.0)
−0.3  
(−2.3 to 1.7)
−1.0  
(−3.1 to 1.1)
0.3  
(−1.3 to 1.9)
−0.1  
(−1.6 to 1.4)
2.4  
(−1.7 to 6.6)
2.9  
(−1.3 to 7.1)
DT indicates distance from the ICA-terminus to the thrombus; and TAI, thrombus attenuation increase.
*Adjusted for age, sex, and thrombus location.
†Adjusted for age and sex.
‡Adjusted for age, sex, and intravenous alteplase treatment.
Table 3. Univariable and Multivariable Binary and Ordinal Logistic Regression for the Relationship of Stroke Cause and Thrombus Characteristics (n=1429)
HAS Higher CBS More Distal Thrombus Location
OR (95% CI) aOR* (95% CI) cOR (95% CI) acOR† (95% CI) cOR (95% CI) acOR† (95% CI)
Cardioembolic (reference) 1 1 1 1 1 1
Noncardioembolic 2.2 (1.6–3.0) 1.5 (1.0–2.1) 0.4 (0.3–0.6) 0.4 (0.3–0.5) 0.2 (0.2–0.3) 0.3 (0.2–0.3)
Undetermined cause 1.1 (0.8–1.3) 0.9 (0.7–1.2) 0.9 (0.8–1.1) 0.9 (0.8–1.1) 0.8 (0.6–0.9) 0.8 (0.6–1.0)
acOR indicates adjusted common odds ratio; aOR, adjusted odds ratio; CBS,  clot burden score; cOR, common odds ratio; HAS, hyperdense artery sign; and OR, odds ratio.
*Adjusted for age, sex, intravenous r-tPA, and thrombus location.
†Adjusted for age and sex.
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tests in this study, we increased our chance of performing type 
I errors (falsely rejecting a null hypothesis). However, results 
for interrelated thrombus characteristics and our sensitivity 
analysis were consistent, and our interpretation was not based 
on P values alone.
For the additional thrombus measurements, the majority 
of patients were excluded because of absence of suitable thin-
section NCCT and CTA, prolonged time between the scanned 
NCCT and CTA (>30 minutes), poorly co-registered scans and 
poor image quality. This selection was mostly the result of a 
large registry of clinical practice, in which thin-section images 
are acquired but then discarded again after producing the 
thick-section reconstructions to limit size of stored data and 
was assumed to be random. Baseline and imaging characteris-
tics for patients with and without suitable imaging for the ad-
ditional thrombus measurements were similar between groups 
(Table II in the Data Supplement), suggesting there was no 
selection bias caused by this limitation. Furthermore, differ-
ences in blood flow caused by the position of the thrombus rel-
ative to the lenticulostriate arteries or other branching arteries, 
could have influenced thrombus length, as thrombus growth 
could be prevented by maintained blood circulation. In our 
study, detailed information on this position was not available; 
however, we did adjust for thrombus location, to partially take 
this factor into account. Calcified thrombi were excluded in 
our study because of their disproportionately high attenuation 
values compared with noncalcified thrombi, possibly affect-
ing outcomes. However, prevalence of calcified thrombus was 
low in our study (<1%), so power for sufficiently assessing a 
relationship with stroke cause was lacking. Future research 
should focus on the relationship of calcified thrombi with 
stroke cause in more detail.
Conclusions
Thrombus CT characteristics of cardioembolic stroke differ 
from those of noncardioembolic stroke. Noncardioembolic 
strokes were associated with presence of HAS, lower CBS, 
shift towards a more proximal thrombus location, higher abso-
lute thrombus attenuation, decrease in distance from the ICA-T 
and longer thrombi, compared with cardioembolic strokes. 
Additionally, our study supports the general hypothesis that 
many cryptogenic strokes have a cardioembolic cause. Further 
research should focus on the use of thrombus CT characteris-
tics as a diagnostic tool for stroke cause in clinical practice.
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